Sg Americas Securities, LLC Outlook Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	BUY	$0.22 - $0.66 $3,855 - $11,567	17,526 Added 87.66%	37,519 $15,000
Q3 2023 Oct 13, 2023	BUY	$0.2 - $1.78 $3,998 - $35,587	19,993 New	19,993 $4,000
Q1 2023 Apr 28, 2023	BUY	$1.0 - $1.35 $61,941 - $83,620	61,941 New	61,941 $68,000
Q3 2022 Oct 31, 2022	BUY	$1.02 - $1.26 $7,365 - $9,098	7,221 Added 40.79%	24,923 $30,000
Q2 2022 Jul 29, 2022	BUY	$0.91 - $2.01 $16,108 - $35,581	17,702 New	17,702 $18,000
Q1 2022 Apr 29, 2022	SELL	$1.22 - $2.03 $30,786 - $51,227	-25,235 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$1.27 - $2.23 $24,883 - $43,692	-19,593 Reduced 43.71%	25,235 $34,000
Q3 2021 Nov 01, 2021	BUY	$2.12 - $2.76 $95,035 - $123,725	44,828 New	44,828 $97,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.